News

Pharm Exec27d
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients over 12 years of age with hemophilia A or B. The ...
Medscape1mon
Antibiotic-Resistant Gonorrhoea Cases Rise in England
Health experts have warned of a rise in antibiotic-resistant gonorrhoea cases in England, including extensively drug-resistant (XDR) strains. New data from the UK Health Security Agency (UKHSA ...
Medscape1mon
Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multistate, Population-Based Analysis
Nearly half of case-infants (47%) were exposed to intrapartum antibiotics, most often for GBS prophylaxis (56% ... 1.0-1.6). Antibiotic susceptibility testing was performed on 457 (70%) of ...
Frontiers3y
Bacterial and Host Determinants of Group B Streptococcal Infection of the Neonate and Infant
Summary of recent studies on antibiotic resistance in neonatal GBS ... will allow for the development of new therapeutics and prophylaxis strategies to better control and prevent invasive GBS disease ...
Frontiers6y
Molecular Characteristics and Antimicrobial Resistance of Group B Streptococcus Strains Causing Invasive Disease in Neonates and Adults
In addition, ST-12 and ST-17 GBS strains showed the highest rate of resistance to erythromycin and clindamycin (range: 75.8–100%). In conclusion, CC-17/type III and CC-1/type VI are the most important ...